The core activity of MV BioTherapeutics SA is the development and application of technologies for regulating the intestinal ecosystem in medical applications, particularly through the ApyraMed/ApyraVax platform. This platform enables the conditional regulation of the intestinal ecosystem to control the adaptive immune response and promote mutualism with intestinal commensals. The company focuses on developing solutions for medical applications, particularly in the fields of mucosal immunology and biomedicine.